JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, cilt.103, sa.5, ss.810-815, 1999 (SCI-Expanded)
Background: There is a significant group of patients with severe asthma who require chronic use of systemic steroids for control of their disease. These patients are at risk for severe side effects from oral steroids. Intravenous immunoglobulin. (IVIG) has immunomodulatory properties, and a few open-label trials have suggested its possible benefit in individuals with severe asthma.